Evidence map›Paper›PMID 25706384›Full record

ArticlePloS one2015

Studies of a murine monoclonal antibody directed against DARC: reappraisal of its specificity.

Dorota Smolarek, Claude Hattab, Anna Buczkowska, Radoslaw Kaczmarek, Anna Jarząb, Sylvie Cochet, Alexandre G de Brevern, Jolanta Lukasiewicz, Wojciech Jachymek, Tomasz Niedziela and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. VInternational journal of molecular sciences · 2022
    Review
  3. MiR-29 Induces K562 Cell Apoptosis by Down-Regulating FoxM1.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Dorota SmolarekLaboratory of Glycoconjugate Immunochemistry Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland; INSERM, UMR_S1134, F-75015 Paris, France; Institut National de la Transfusion Sanguine, F-75015 Paris, France; Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, King's College London, Guy's Hospital, London, United Kingdom.
Claude HattabINSERM, UMR_S1134, F-75015 Paris, France; Institut National de la Transfusion Sanguine, F-75015 Paris, France; Universite Paris-Diderot, Sorbonne Paris Cité, F-15013, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.
Anna BuczkowskaLaboratory of Glycoconjugate Immunochemistry Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland; Institute of Biochemistry and Biophysics, Warsaw, Poland.
Radoslaw KaczmarekLaboratory of Glycoconjugate Immunochemistry Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Anna JarząbLaboratory of Medical Microbiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Sylvie CochetINSERM, UMR_S1134, F-75015 Paris, France; Institut National de la Transfusion Sanguine, F-75015 Paris, France; Universite Paris-Diderot, Sorbonne Paris Cité, F-15013, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.
Alexandre G de BrevernINSERM, UMR_S1134, F-75015 Paris, France; Institut National de la Transfusion Sanguine, F-75015 Paris, France; Universite Paris-Diderot, Sorbonne Paris Cité, F-15013, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.
Jolanta LukasiewiczLaboratory of Microbial Immunochemistry and Vaccines Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Wojciech JachymekLaboratory of Microbial Immunochemistry and Vaccines Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Tomasz NiedzielaLaboratory of Microbial Immunochemistry and Vaccines Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Magdalena GrodeckaLaboratory of Glycoconjugate Immunochemistry Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland.
Kazimiera WasniowskaLaboratory of Glycoconjugate Immunochemistry Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland; Institute of Physiotherapy, Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland.
Yves Colin AronoviczINSERM, UMR_S1134, F-75015 Paris, France; Institut National de la Transfusion Sanguine, F-75015 Paris, France; Universite Paris-Diderot, Sorbonne Paris Cité, F-15013, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.
Olivier BertrandINSERM, UMR_S1134, F-75015 Paris, France; Institut National de la Transfusion Sanguine, F-75015 Paris, France; Universite Paris-Diderot, Sorbonne Paris Cité, F-15013, Paris, France; Laboratory of Excellence GR-Ex, Paris, France.
Marcin CzerwinskiLaboratory of Glycoconjugate Immunochemistry Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland; Institute of Physiotherapy, Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland.
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy · PLOpole University of Technology · PLSorbonne Paris Cité · FRInserm · FRInstitut National de la Transfusion Sanguine · FRLaboratory of Excellence GR-Ex · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duffy Antigen Receptor for Chemokines (DARC) plays multiple roles in human health as a blood group antigen, a receptor for chemokines and the only known receptor for Plasmodium vivax merozoites. It is the target of the murine anti-Fy6 monoclonal antibody 2C3 which binds to the first extracellular domain (ECD1), but exact nature of the recognized epitope was a subject of contradictory reports. Here, using a set of complex experiments which include expression of DARC with amino acid substitutions within the Fy6 epitope in E. coli and K562 cells, ELISA, surface plasmon resonance (SPR) and flow cytometry, we have resolved discrepancies between previously published reports and show that the basic epitope recognized by 2C3 antibody is 22FEDVW26, with 22F and 26W being the most important residues. In addition, we demonstrated that 30Y plays an auxiliary role in binding, particularly when the residue is sulfated. The STD-NMR studies performed using 2C3-derived Fab and synthetic peptide corroborated most of these results, and together with the molecular modelling suggested that 25V is not involved in direct interactions with the antibody, but determines folding of the epitope backbone.

Indexed as

Antibodies, MonoclonalAnimalsAntibody SpecificityBinding Sites, AntibodyDuffy Blood-Group SystemEpitopesEscherichia coliHumansMiceReceptors, Cell SurfaceACKR1 protein, humanAntibodies, MonoclonalDuffy Blood-Group SystemEpitopesReceptors, Cell Surface

Identifiers

PMID25706384
PMCPMC4338028
OpenAlexW1996585925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.